

Under the Paperwork Reduction Act of 1996, no person is required to respond to a collection of information unless it displays a valid OMB control number.

## POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

Practitioner associated with the Customer Number: **45511**

OR

Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

The address associated with Customer Number: **45511**

OR

<input type="checkbox"/> Firm or Individual Name:	
Address:	
City:	State:
Country:	Zip:
Telephone:	Email:

Assignee Name and Address:

Janssen Pharmaceuticals N.V.  
Turnhoutseweg 30  
B-2340 Borssele, Belgium

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/65 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

**SIGNATURE of Assignee of Record**  
The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature:	<i>Mary A. Appollina</i>	Date:	5-13-05
Name:	Mary A. Appollina	Telephone:	732-524-3742
Title:	Proxy Holder		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to be (and by the USPTO to be) provided by 37 CFR 1.31 and 1.32 and 37 CFR 1.33. This collection is subject to the 3.0 burden reduction rule. 3.0 includes the following: reducing burdens, and automating or simplifying the process to the USPTO. Any comments concerning the burden of this collection of information should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22312-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22312-1450.

If you need assistance in completing this form, call 1-800-PTO-9191 and select option 2.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In Re Application of: FREYNE, et al.****Confirmation No: 8098****Application No.: 10/565,065****Group Art Unit: 1624****Filing Date: January 17, 2006****Examiner: SUSANNA MOORE****Title: TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE  
KINASE 3 INHIBITORS****STATEMENT UNDER 37 CFR § 3.73(b)**

JANSSEN PHARMACEUTICA N.V., a CORPORATION, states:

- that it is the assignee of the entire right, title, and interest in the patent application identified above by virtue of an assignment from the inventors of the patent application.
- The assignment was recorded in the Patent and Trademark Office at Reel 017487, Frame 0329.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Date:

*3/20/07*  
Name: S. Maurice Valla  
Attorney for Applicant  
Registration No. 43, 996

Woodcock Washburn LLP  
Cira Centre  
2929 Arch Street, 12th Floor  
Philadelphia, PA 19104-2891  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439